Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

279
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
279
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

445
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
445
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

288
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
288
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

1.9K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.9K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

315
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
315
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

357
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
357

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What influences engagement with a bipolar disorder self-management app? A qualitative investigation of use of the PolarUs app.

PLOS digital health·2025
Same author

The experience of self-monitoring using the PolarUs bipolar disorder self-management app: a qualitative report of impacts and unmet needs.

Journal of affective disorders·2025
Same author

Controlling Diabetes: Continuous Glucose Monitoring for the Older Adult.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists·2018
Same author

An open circuit voltage decay system for performing injection dependent lifetime spectroscopy.

The Review of scientific instruments·2017
Same author

Vaccines for Older Adults.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists·2017
Same author

An evaluation system for experimental silicon and silicon carbide super gate turn off thyristors.

The Review of scientific instruments·2014

Related Experiment Video

Updated: Sep 22, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.4K

Pharmacology: Non-Insulin Agents.

Heather O'Brien1, Catherine Travis2

  • 1Southern Regional Area Health Education Center, 1601 Owen Drive, Fayetteville, NC 28304, USA.

Primary Care
|May 20, 2022
PubMed
Summary

New diabetes medications, including SGLT2 inhibitors and GLP-1 agonists, offer significant benefits beyond glucose control. These agents provide cardiovascular and renal protection, aiding in weight loss and minimizing hypoglycemia risk.

Keywords:
Diabetes pharmacologyDiabetes treatmentNon-insulinType 2 diabetes

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.8K
An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.8K

Related Experiment Videos

Last Updated: Sep 22, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.4K
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.8K
An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.8K

Area of Science:

  • Endocrinology
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Type 2 diabetes management is evolving beyond traditional therapies.
  • Metformin remains a cornerstone, but newer drug classes are gaining prominence.

Purpose of the Study:

  • To review the current landscape of type 2 diabetes pharmacotherapy.
  • To highlight the benefits and guideline recommendations for newer medication classes.

Main Methods:

  • Review of recent clinical guidelines and landmark studies.
  • Analysis of efficacy, safety, and long-term outcomes of key diabetes medications.

Main Results:

  • Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 agonists demonstrate high efficacy.
  • These classes offer significant cardiovascular and renal protective benefits.
  • Weight loss and a low risk of hypoglycemia are additional advantages.

Conclusions:

  • Newer pharmacotherapies are essential for comprehensive type 2 diabetes management.
  • Shared decision-making and patient-centered approaches are crucial for optimizing treatment outcomes.